No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TVTX Travere Therapeutic
- 5.720
- -0.080-1.38%
Close Apr 19 16:00 ET
- 5.750
- +0.030+0.52%
Post 19:02 ET
435.34MMarket Cap-3813P/E (TTM)
5.910High5.575Low946.78KVolume5.730Open5.800Pre Close5.43MTurnover1.56%Turnover RatioLossP/E (Static)76.11MShares22.75052wk High2.17P/B346.37MFloat Cap5.25052wk Low--Dividend TTM60.55MShs Float37.040Historical High--Div YieldTTM5.78%Amplitude0.000Historical Low5.736Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Reported Earlier, Travere Therapeutics And CCL Vifor Get European Commission Approval Of Sparsentan For The Treatment Of IgA Nephropathy
Travere Therapeutics, Inc. (NASDAQ:TVTX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 3x Travere Therapeutics, Inc. (NASDAQ:TVTX) is definitely a stock worth checking out, seeing as almost half of all the Biotechs companies i
FYBR, BCRX and SABR Are Among After Hour Movers
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
4 analysts have shared their evaluations of Travere Therapeutics (NASDAQ:TVTX) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table provides a quick
Express News | Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
As More Rare Disease Therapies Launch, Their Prices Are Rising
Comments
🎯 Ph 3 readouts in Q2 2024...
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
17
The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.
1
Update
$Travere Therapeutic(TVTX.US$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Travere Therapeutics' future revenue performance is expected to decline, contributing to its low P/S. Shareholders accept this as they anticipate no pleasant surprises in future revenue. A strong share price rise seems unlikely under these circumstances.
Update
$Travere Therapeutic(TVTX.US$ Travere Therapeutics Has Opened Enrollment In HARMONY Phase 3 Trial Of Pegtibatinase For Classical Homocystinuria Compared To Placebo In Participants Who Are Receiving Standard Of Care
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg